anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a lactobacillus reuteri A21099 with an anti-tumor effect and application thereof, wherein the strain is preserved in the microorganism strain preservation center of Guangdong province, and the preservation address is as follows: building 5, no. 59, of the first university of middle road 100, guangzhou City, guangdong, with a deposit number of GDMCC No.62831 and a deposit date of 2022, 9 months and 23 days. The strain is obtained by screening feces of long-life rural healthy century old people, has remarkable anti-tumor effect in a colon cancer tumor mouse model, can inhibit tumor growth, and improves intestinal microecology. The capacity of the strain for producing the reuterin by conversion per milliliter reaches 2.36mmol/L, and the reuterin produced by metabolism has the capacity of inhibiting the growth of gram-positive bacteria and gram-negative bacteria. The lactobacillus reuteri also has the activities of resisting artificial gastrointestinal fluid and bile salt, and can ensure that the strain is planted in a complex intestinal environment. In addition, the strain can be used as intestinal probiotics and applied to the field of foods to prepare products such as fermented milk, yoghurt, probiotic preparations and the like.
The plant alkaloid homoharringtonine (HHT) is a Food and Drug Administration (FDA)-approved drug for the treatment of hematologic malignancies. In addition to its well-established antitumor activity, accumulating evidence attributes anti-inflammatory effects to HHT, which have mainly been studied in leukocytes to date. However, a potential influence of HHT on inflammatory activation processes in endothelial cells, which are a key feature of inflammation and a prerequisite for the leukocyte-endothelial cell interaction and leukocyte extravasation, remains poorly understood. In this study, the anti-inflammatory potential of HHT and its derivative harringtonine (HT) on the TNF-induced leukocyte-endothelial cell interaction was assessed, and the underlying mechanistic basis of these effects was elucidated. HHT affected inflammation in vivo in a murine peritonitis model by reducing leukocyte infiltration and proinflammatory cytokine expression as well as ameliorating abdominal pain behavior. In vitro, HT and HHT impaired the leukocyte-endothelial cell interaction by decreasing the expression of the endothelial cell adhesion molecules intracellular adhesion molecule -1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). This effect was mediated by a bipartite mechanism. While HHT did not affect the prominent TNF-induced pro-inflammatory NF-ĸB signaling cascade, the compound downregulated the VCAM1 mRNA expression in an IRF-1-dependent manner and diminished active ICAM1 mRNA translation as determined by polysome profiling. This study highlights HHT as an anti-inflammatory compound that efficiently hampers the leukocyte-endothelial cell interaction by targeting endothelial activation processes.
Ligands that are capable of forming metal complexes are incorporated directly into peptides at nonbiologically active locations. The metal complex serves as a bifunctional agent and as a spacer molecule. In one aspect of the invention, the ligands are prepared by replacing a nonbiologically active peptide spacer sequence with either Cys-Gly-Gly-Glu(η-)CO- (SEQ ID NO:1) or Cys-Gly-Gly-Lys(ε-)NH-CO(CH2)2-CO- (SEQ ID NO:2). In these examples, unnatural peptide bonds are used to attach the ligand to the terminal end of the peptide. Peptides incorporating such ligands are also disclosed. Other spacer ligands which may be incorporated into peptides include the following natural peptide sequences: -Cys-Gly-His-, -Asp-Gly-Cys-, -Glu-Gly-Cys-, -Gly-Asp-Cys-, and -Gly-Glu-Cys-. Unnatural tripeptides which function as spacer ligands include: -Cys-Gly-(imidazolyl glycyl)-, -isoCys-Gly-(imidazolyl glycyl)-, and -isoCys-Gly-His-. When the above peptide sequences are present in a nonbiologically active peptide spacer, they are able to form metal complexes with desired metal ions, and the resulting complexes serve as bifunctional agents and as spacer molecules in the peptide.
The invention relates to a puerarin mask, especially a puerarin mask adopting puerarin estrogen. The mask is formed by adding water into puerarin, performing heating, and cooling the mixture in a mask mold. The mask provided by the invention employs puerarin to whiten skin, can prolong life, and is a natural plant skin whitening medicinal and edible mask suitable for people of all ages. The mask is also an excellent product eatable as breakfast. Puerarin contains a variety of flavonoid components, and the main active ingredients include daidzein, daidzin, puerarin, and puerarin-7-xyloside, etc. The puerarin contains human physiological active substances, is a natural plant skin whitening and life prolonging mask product suitable for people of all ages. The plant can meet requirements, reduce the cost and save cost.
A pre-clinical toxicological evaluation of herbal medicines is necessary to identify any underlying health-associated side effects, if any. BPGrit is an Ayurveda-based medicine prescribed for treating hypertensive conditions. High-performance liquid chromatography-based analysis revealed the presence of gallic acid, ellagic acid, coumarin, cinnamic acid, guggulsterone E, and guggulsterone Z in BPGrit. For sub-acute toxicity analysis of BPGrit, male and female Sprague-Dawley rats were given repeated oral gavage at 100, 300, and 1000 mg/kg body weight/day dosages for 28 days, followed by a 14-day recovery phase. No incidences of mortality, morbidity, or abnormal clinical signs were observed in BPGrit-treated rats throughout the study period. Also, the body weight and food consumption habits of the experimental animals did not change during the study duration. Hematological, biochemical, and histopathological analysis did not indicate any abnormal changes occurring in the BPGrit-treated rats up to the highest tested dose of 1000 mg/kg body weight/day. Finally, the study established the "no-observed-adverse-effect level" for BPGrit at >1000 mg/kg body weight/day in Sprague-Dawley rats.
PROBLEM TO BE SOLVED: To obtain a pharmaceutical preparation capable of improving fluidity of powder and compression moldability (tableting property) and imparting sustain release property by using a carrier composed of a specific hydroxypropylmethyl cellulose and hydrogen calcium phosphate. SOLUTION: This pharmaceutical preparation comprises (A) an active ingredient, (B) hydroxypropylmethyl cellulose and (C) (anhydrous)hydrogen calcium phosphate. A water soluble active component, preferably phenylpropanolamine hydrochloride is used as the component A. The component B has preferably 19-24wt.% methoxy content and 4-12wt.% hydroxypropoxy content. The component C is blended in an amount of 5-100 pts.wt. based on 100 pts.wt. component B. Further, the pharmaceutical preparation contains a crystalline cellulose in an amount of 1-50 pts.wt. based on 100 pts.wt. component B. As a result, the preparation can contain a large amount of the component B and can be slowly released even when the preparation is a water-soluble medicine.
<P>PROBLEM TO BE SOLVED: To provide a novel method of treating localized solid tumors and papillomas in an individual as well as metastatic carcinoma.  <P>SOLUTION: The therapy comprises delivering a suicide gene, by way of a recombinant adenoviral vector or other DNA transport system, into the tumor, papilloma or wart of an individual. Subsequently, a prodrug, such as the drug gaciclovir(R), is administered to the individuals. Additionally, the therapy provides a method for treating solid tumors, papillomas, warts and metastatic carcinomas, the method comprising introducing both a suicide gene and one or more cytokine gene into the tumor, papilloma or wart of an individual, and subsequently administering a prodrug to the individual. The methods may be used to treat several different types of cancers and papillomas, including colon carcinoma, prostate cancer, breast cancer, lung cancer, melanoma, hepatoma, brain lymphoma and head and neck cancer.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The invention provides a preparation method and application of a biotin-cytarabine prodrug, and relates to the field of pharmaceutical chemicals. The invention prepares a series of biotin-cytarabine prodrugs by introducing a linker to couple biotin and cytarabine. The reaction condition of the invention is mild, and the prepared series of biotin-cytarabine prodrugs have remarkable beneficial effects. The series of prodrugs enter tumor cells through biotin targeting binding with biotin receptors on the surfaces of the tumor cells, and after entering the cells, cytarabine is released through disulfide bond or amide bond cleavage to play an anti-tumor role. The biotin-cytarabine prodrug can improve the uptake of cytarabine by tumor cells, has better killing effect on tumor cells and shows stronger anti-tumor curative effect compared with the cytarabine prodrug. Therefore, the series of biotin-cytarabine prodrugs have good application prospect and beneficial effects.
Subjects will undergo estradiol administration for up to 9 days. Transdermal estradiol patches will be applied each day by study staff during study days two through nine (patches deliver 0.1 mg/day for a total dose of up to 0.6 mg/day).
The invention relates to novel biocompatible hybrid nanoparticles of very small size that are of use in particular for diagnosis and/or therapy. The objective of the invention is to provide novel nanoparticles which are of use in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which are more effective than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high metal (e.g. rare earth) loading rate, in particular so as to have, in imaging (e.g. MRI), a strong enhancement and a correct response (increased relaxivity) at high frequencies. Thus, the nanoparticles according to the invention, of diameter d 1  between 1 and 20 nm, each comprise a polyorganosiloxane (POS) matrix including gadolinium cations, optionally associated with doping cations; a DTPABA (diethylenetriaminepentaacetic acid bisanhydride) chelating C 1  graft bonded to the POS matrix via -Si-C- covalent bonding, and present in sufficient amount to be able to complex all the gadolinium cations; and optionally an other functionalization graft Gf* bonded to the POS matrix via -Si-C- covalent bonding (it being possible for Gf* to result from a hydrophilic compound (PEG); from a compound comprising an active ingredient PA1; from a targeting compound; from a luminescent compound (fluorescein)). The method for obtaining these nanoparticles and the uses thereof in imaging and in therapy are also part of the invention.
Participants in this group will be placed on a diet that is prescribed a 25% reduction from maintenance calories (calories to maintain current body weight) with a dietary protein intake of 1.2 g of protein/kg body mass and remaining calories split evenly between fat and carbohydrate. In this group they will adhere to a 25% caloric reduction daily for 12 weeks.
The invention relates to a traditional Chinese medicine composition for treating senile cutaneous pruritus. The traditional Chinese medicine composition is prepared from the following bulk drugs by weight: 5 to 15 parts of sophora flavescens and 5 to 15 parts of broom cypress fruit. The invention further provides application of the traditional Chinese medicine composition in treating senile cutaneous pruritus. The composition belongs to Chinese herbal medicine compound preparations; compatibility of the bulk drugs of the composition accords with the principles of monarch, minister, assistant and guide; according to results of pharmacodynamic experiments, the composition exerts a good curative effect on patients with senile cutaneous pruritus and provides a novel method for treatment of senile cutaneous pruritus. According to the invention, a sponge bath method is cooperatively used to allow soup to directly contact with the skin, thereby exerting a drug effect to treat senile cutaneous pruritus; the advantages of a simple approach, convenience in usage, low cost for the soup, no side-effects, etc. are obtained, so the traditional Chinese medicine composition has good application prospects.
Serious acute hypersensitivity reactions during acetylcysteine administration including rash, hypotension, wheezing, and/or shortness of breath, have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose and occurred soon after initiation of the infusion [see Adverse Reactions (6.1)]. If a severe hypersensitivity reaction occurs, immediately stop the infusion of Acetylcysteine injection and initiate appropriate treatment. 

One patient with asthma developed bronchospasm and died after intravenous administration of acetylcysteine. Acetylcysteine injection should be used with caution in patients with asthma, or where there is a history of bronchospasm. Patients with asthma should be closely monitored during initiation of Acetylcysteine injection therapy and throughout Acetylcysteine injection therapy.

Acute flushing and erythema of the skin may occur in patients receiving acetylcysteine intravenously. These reactions usually occur 30 to 60 minutes after initiating the infusion and often resolve spontaneously despite continued infusion of acetylcysteine. If a reaction to acetylcysteine involves more than simply flushing and erythema of the skin, it should be treated as a hypersensitivity reaction.

Management of less severe hypersensitivity reactions should be based upon the severity of the reaction and include temporary interruption of the infusion and/or administration of antihistaminic drugs. The Acetylcysteine injection infusion may be carefully restarted after treatment of the hypersensitivity symptoms has been initiated; however, if the hypersensitivity reaction returns upon re-initiation of treatment or increases in severity, Acetylcysteine injection should be discontinued and alternative patient management should be considered.
Antibiotic compounds having both antibiotic and aggregation-induced emission (AIE) characteristics. The compounds comprise an azole antibiotic unit, for example naphthalimide triazole (NT), and an AIE unit, for example triphenylethylene (TriPE). The compounds act as an effective AIEgen with ROS generating capabilities. The present combinations of an azole antibiotic unit and an AIE unit do not negatively affect the antibacterial properties of the azole. Accordingly, the present compounds exterminate bacteria with both the antibacterial mechanism of the azole along with the ROS produced when the AIE unit is exposed to light. In addition, the intrinsic imagining ability of the present compounds enables them to be used as imaging tools to monitor the drug-bacteria interaction. Collectively, the present compounds provide multiple functions including imaging, monitoring, and bacterial infection inhibition for integrated diagnosis and treatment in clinical practices.
Neovascular age-related macular degeneration (AMD) is caused by an ingrowth of pathological vessels under the macula. Experimental studies have demonstrated that vascular endothelial growth factor (VEGF) is centrally involved in this process. For this reason, anti-VEGF drugs, in particular ranibizumab, as become the treatment of choice for neovascular AMD. Ranibizumab use is limited by its high cost. Also, ranibizumab requires repeated (sometimes up to monthly) intravitreal injections for many years. Strategies to reduce the burden of this treatment on the patient as well as on the health care system will be critical. Combination therapy is an attractive such possibility. Transpupillary thermotherapy (TTT) is a technique by which vascular occlusion can be induced by delivering radiation at near infrared intensity to the target tissue through the pupil. Several reports have indicated that TTT may be used to slow disease progression in patients with neovascular AMD. In this study we examine whether combined ranibizumab and TTT will reduce the number of ranibizumab injections compared with ranibizumab alone (sham TTT). The study will go on for 2 years with an interim report after 1 year.
In preclinical studies in rats, tipranavir treatment induced dose-dependent changes in coagulation parameters (increased prothrombin time, increased activated partial thromboplastin time, and a decrease in some vitamin K dependent factors). In some rats, these changes led to bleeding in multiple organs and death. The co-administration of vitamin E in the form of TPGS (d-alpha-tocopherol polyethylene glycol 1000 succinate) with tipranavir resulted in a significant increase in effects on coagulation parameters, bleeding events, and death.

In preclinical studies of tipranavir in dogs, an effect on coagulation parameters was not seen. Co-administration of tipranavir and vitamin E has not been studied in dogs. Clinical evaluation of coagulation effects on HIV-1-infected subjects demonstrated no tipranavir plus ritonavir effect on coagulation parameters [see Warnings and Precautions (5.5)].
A rapid review was conducted to explore the implementation determinants of human papillomavirus (HPV) vaccination in the World Health Organization African Region and describe their dynamic relationship. PubMed and Google Scholar were searched in October 2023 to find relevant literature. A total of 64 published studies that reported factors affecting HPV vaccination were identified. Analysis of identified factors yielded 74 implementation determinants of HPV vaccination across the five domains of the Consolidated Framework for Implementation Research (CFIR): two (2.70%) were in the innovation domain, seven (9.46%) were in the outer setting domain, 14 (18.92%) were in the inner setting domain, 37 (50%) were in the individual domain and 14 (18.92%) were in the implementation process domain. A causal loop diagram of these implementation determinants revealed four balancing and seven reinforcing loops. Applying systems lens promoted a more holistic understanding of the implementation determinants of HPV vaccination, exposing leverage points for interventions.
This is a Phase 1/2, open-label study designed to evaluate the safety, tolerability and procedure of a microneedle injection of triamcinolone acetonide (TA) into the SCS. The subjects enrolled in this study will be chosen from subjects with non-infectious intermediate, posterior and pan-uveitis. The injection will only be administered to a single eye via the Clearside Biomedical proprietary microneedle into the SCS. The dose of TA to be injected is 4 mg of currently approved TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL). The study design includes 10 clinic visits over 27 weeks. Subjects will be followed for 26 weeks following treatment with TRIESENCE®.
Local anesthesia is commonly used in oral health care and intra-mucosal infiltration anesthesia is most commonly used by practitioners. Anesthesia may cause children a great deal of anxiety because of the fear of the injection. The latter can be painful if the product is delivered too quickly in the mucosa. Recent developments in the techniques and anesthesia systems allow reducing pain during the injection. In particular, computerized systems (electronically assisted local anesthesia) allow a slow injection limiting pressure. Moreover, these systems look like a pen which prevents the negative impression of the image related to the syringe metal. The intraosseous electronically-assisted anesthesia could be an interesting alternative to conventional infiltration anesthesia by making the act less stressful but also less painful for the child.
Crossover study: Participants will be consuming placebo on a clinic day at least 1 week prior to a clinic day where they will consume the active intervention. Following the second clinic day, the participant will consume active intervention for 7 days. The participant will then undergo a washout period of 7 days.
PURPOSE: Obesity and preeclampsia share similar patho-mechanisms and can both affect placental pathology. We aimed to investigate pregnancy outcomes in correlation with placental pathology among pregnancies complicated by preeclampsia in three different maternal body mass index (BMI, kg/m2) groups.
METHODS: In this retrospective cohort study, medical and pathological records of patients with preeclampsia and a singleton pregnancy delivered between 2008 and 2021 at a single tertiary medical center were reviewed. Study population was divided into three BMI groups: BMI < 22.6 kg/m2 (low BMI group), 22.7 ≤ BMI ≤ 28.0 kg/m2 (middle-range BMI group), and BMI > 28.0 kg/m2 (high BMI group). Data regarding maternal characteristics, neonatal outcomes, and placental histopathological lesions were compared.
RESULTS: The study groups included a total of 295 patients diagnosed with preeclampsia-98, 99, and 98 in the low, middle-range, and high BMI groups respectively. Neonatal birth weight was significantly decreased in the low maternal BMI group compared to both middle and high BMI groups (p = 0.04) with a similar trend seen in placental weight (p = 0.03). Villous changes related to maternal malperfusion were more prevalent in the low and high BMI groups compared to middle-range BMI group (p < 0.01) and composite maternal vascular malperfusion lesions were also more prevalent in the groups of BMI extremities compared to the middle-range BMI group (p < 0.01).
CONCLUSION: Maternal BMI might influence neonatal outcomes and placental pathology in pregnancies complicated by preeclampsia. Both extremes of BMI were associated with higher rates of placental maternal vascular malperfusion. Balanced BMI in women at risk for preeclampsia may reduce the incidence of placental lesions.